XORTX Therapeutics (XRTX) Net Income towards Common Stockholders (2020 - 2026)
XORTX Therapeutics (XRTX) posted Net Income towards Common Stockholders of -$823297.0 for Q1 2026, up 84.25% on a QoQ basis from -$5.2 million in Q4 2025, and up 14.55% year-over-year from -$718738.4 in Q1 2025.
XORTX Therapeutics (XRTX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$823297.0 for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.55% year-over-year to -$823297.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 140.12% YoY) and the FY2025 annual result came in at $1.9 million, down 21.44% from the prior year.
- Net Income towards Common Stockholders was -$823297.0 for Q1 2026 at XORTX Therapeutics, up from -$5.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $143709.0 in Q4 2024 and bottomed at -$5.2 million in Q4 2025.
- A 5-year average of -$1.4 million and a median of -$1.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 52.86% — and 2025, when it tumbled 3736.45%.
- XORTX Therapeutics' Net Income towards Common Stockholders stood at -$1.6 million in 2022, then advanced by 12.02% to -$1.4 million in 2023, then jumped by 110.31% to $143709.0 in 2024, then tumbled by 3736.45% to -$5.2 million in 2025, then jumped by 84.25% to -$823297.0 in 2026.
- Business Quant data shows XRTX's Net Income towards Common Stockholders at -$823297.0 in Q1 2026, -$5.2 million in Q4 2025, and -$716197.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -0.68 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | -823,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -823,297.00 |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -716,197.00 |
| Jun 30, 2025 | -889,945.00 |
| Mar 31, 2025 | -963,456.00 |
| Dec 31, 2024 | 143,709.00 |
| Sep 30, 2024 | -874,749.00 |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -1.09 Mn |
| Sep 30, 2023 | -1.39 Mn |
| Jun 30, 2023 | -1.26 Mn |
| Mar 31, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.58 Mn |
| Sep 30, 2022 | -917,922.54 |
| Jun 30, 2022 | -971,672.58 |
| Mar 31, 2022 | -2.87 Mn |
| Dec 31, 2021 | 308,203.93 |
| Sep 30, 2021 | -321,636.47 |
| Jun 30, 2021 | -704,063.01 |
| Mar 31, 2021 | -608,734.24 |